Institute for Health Metrics and Evaluation, Seattle, WA, USA.
World Health Organization, Geneva, Switzerland.
Lancet Infect Dis. 2020 Aug;20(8):929-942. doi: 10.1016/S1473-3099(20)30124-9. Epub 2020 Apr 23.
Estimates of government spending and development assistance for tuberculosis exist, but less is known about out-of-pocket and prepaid private spending. We aimed to provide comprehensive estimates of total spending on tuberculosis in low-income and middle-income countries for 2000-17.
We extracted data on tuberculosis spending, unit costs, and health-care use from the WHO global tuberculosis database, Global Fund proposals and reports, National Health Accounts, the WHO-Choosing Interventions that are Cost-Effective project database, and the Institute for Health Metrics and Evaluation Development Assistance for Health Database. We extracted data from at least one of these sources for all 135 low-income and middle-income countries using the World Bank 2019 definitions. We estimated tuberculosis spending by source and function for notified (officially reported) and non-notified tuberculosis cases separately and combined, using spatiotemporal Gaussian process regression to fill in for missing data and estimate uncertainty. We aggregated estimates of government, out-of-pocket, prepaid private, and development assistance spending on tuberculosis to estimate total spending in 2019 US$.
Total spending on tuberculosis in 135 low-income and middle-income countries increased annually by 3·9% (95% CI 3·0 to 4·6), from $5·7 billion (5·2 to 6·5) in 2000 to $10·9 billion (10·3 to 11·8) in 2017. Government spending increased annually by 5·1% (4·4 to 5·7) between 2000 and 2017, and reached $6·9 billion (6·5 to 7·5) or 63·5% (59·2 to 66·8) of all tuberculosis spending in 2017. Of government spending, $5·8 billion (5·6 to 6·1) was spent on notified cases. Out-of-pocket spending decreased annually by 0·8% (-2·9 to 1·3), from $2·4 billion (1·9 to 3·1) in 2000 to $2·1 billion (1·6 to 2·7) in 2017. Development assistance for country-specific spending on tuberculosis increased from $54·6 million in 2000 to $1·1 billion in 2017. Administrative costs and development assistance for global projects related to tuberculosis care increased from $85·3 million in 2000 to $576·2 million in 2017. 30 high tuberculosis burden countries of low and middle income accounted for 73·7% (71·8-75·8) of tuberculosis spending in 2017.
Despite substantial increases since 2000, funding for tuberculosis is still far short of global financing targets and out-of-pocket spending remains high in resource-constrained countries, posing a barrier to patient's access to care and treatment adherence. Of the 30 countries with a high-burden of tuberculosis, just over half were primarily funded by government, while others, especially lower-middle-income and low-income countries, were still primarily dependent on development assistance for tuberculosis or out-of-pocket health spending.
Bill & Melinda Gates Foundation.
针对结核病的政府支出和发展援助的估计数已经存在,但对于自费和预付私人支出的了解则较少。我们旨在为 2000 年至 2017 年期间的低收入和中等收入国家的结核病总支出提供全面的估计数。
我们从世卫组织全球结核病数据库、全球基金提案和报告、国家卫生账户、世卫组织选择具有成本效益的干预措施项目数据库以及卫生计量与评估研究所发展援助健康数据库中提取了有关结核病支出、单位成本和卫生保健使用的数据。我们使用 2019 年世界银行的定义,从至少一个上述来源中提取了 135 个低收入和中等收入国家的所有数据。我们分别和合并报告(官方报告)和非报告结核病病例的结核病支出按来源和功能进行估计,使用时空高斯过程回归来填补缺失数据并估计不确定性。我们汇总了政府、自费、预付私人和发展援助对结核病的支出估计数,以估计 2019 年的 2019 年美国结核病总支出。
在 135 个低收入和中等收入国家中,结核病支出每年以 3.9%(95%CI 3.0 至 4.6)的速度增长,从 2000 年的 57 亿美元(5.2 至 6.5)增加到 2017 年的 109 亿美元(10.3 至 11.8)。2000 年至 2017 年期间,政府支出每年以 5.1%(4.4 至 5.7)的速度增长,到 2017 年达到 69 亿美元(6.5 至 7.5)或所有结核病支出的 63.5%(59.2 至 66.8)。政府支出中,有 58 亿美元(5.6 至 6.1)用于报告病例。自费支出每年以 0.8%(-2.9 至 1.3)的速度下降,从 2000 年的 24 亿美元(1.9 至 3.1)下降到 2017 年的 21 亿美元(1.6 至 2.7)。针对结核病的国家特定支出的发展援助从 2000 年的 5460 万美元增加到 2017 年的 11 亿美元。与结核病护理相关的全球项目的行政费用和发展援助从 2000 年的 8530 万美元增加到 2017 年的 5.762 亿美元。30 个结核病负担高的中低收入国家占 2017 年结核病支出的 73.7%(71.8-75.8)。
尽管自 2000 年以来有了大幅增加,但结核病资金仍远低于全球融资目标,而且资源有限的国家自费支出仍然很高,这对患者获得护理和治疗的依从性构成了障碍。在 30 个结核病负担沉重的国家中,超过一半主要由政府提供资金,而其他国家,尤其是中低收入和低收入国家,仍然主要依赖结核病发展援助或自费卫生支出。
比尔及梅琳达·盖茨基金会。